MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2020

On November 11, 2020 MEDIVIR AB reported that – INTERIM REPORT JANUARY – SEPTEMBER 2020 (Press release, Medivir, NOV 11, 2020, View Source;interim-report-january–september-2020-301169439.html [SID1234570648])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Continued focus on MIV-818

July – September
Significant events during the quarter

In July, a research collaboration was initiated with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get access to Medivir’s unique proprietary protease-targeted compound library.
Financial summary for the quarter

Net turnover amounted to SEK 1.1 (1.7) million.
The profit before interest, tax, depreciation and amortization (EBITDA) amounted to SEK 5.2 (-22.0) million. Basic and diluted earnings per share amounted to SEK 0.19 (-0.95) and SEK 0.19 (-0.95) respectively.
Cash flow from operating activities amounted to SEK -17.1 (-31.8) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 82.7 (158.5) million.
January – September
Financial summary

Net turnover amounted to SEK 12.5 (7.3) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -27.9 (-88.6) million. Basic and diluted earnings per share amounted to SEK -1.30 (-3.76) and SEK -1.30 (-3.76) respectively.
Cash flow from operating activities amounted to SEK -57.1 (-125.3) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 82.7 (158.5) million.
Significant events after the end of the quarter

In October Dr. Tom Morris was appointed interim Chief Medical Officer. Dr. Morris will report to CEO Yilmaz Mahshid and be a member of Medivir’s management team.
Conference call for investors, analysts and the media
The Interim Report January – September 2020 will be presented by Medivir’s President & CEO, Yilmaz Mahshid.

Time: Tuesday, November 10, 2020, at 14.00 (CET).

Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020

On November 11, 2020 Sosei Group Corporation ("the Company"; TSE: 4565) reported an update on operational activities and reports its consolidated results for the nine months ended 30 September 2020 (Press release, Sosei, NOV 11, 2020, View Source [SID1234570627]). The full report is attached or can be accessed by clicking here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: "The past quarter has seen Sosei Heptares maintain excellent levels of operational activity and continue to make good progress driving its growth strategy forwards despite the ongoing pandemic.

"The new funds we secured in July, will allow us to identify and execute strategic opportunities to accelerate our long-term growth through organic and inorganic means. We are evaluating several such opportunities and expect a number of these to come to fruition.

"In addition, our business development remains very active as we seek to generate value from our pipeline through both traditional discovery and development partnerships and novel VC-backed spin-out companies.

"We were very excited therefore with the creation of Tempero Bio, which has been established by Aditum Bio to advance the clinical development of our mGlu5 NAM programme in addiction and anxiety. This agreement further demonstrates the high quality of candidates we can design and develop and in turn the high quality of partner these can attract.

"We continue to believe that we have all the elements in place to drive our continued success and we look forward to updating our shareholders as we reach future value-creating milestones."

Operational Highlights for Q3 2020

Approximately US$195 million raised from International Offering of shares and convertible bonds – the Company intends to use most of the funds to pursue strategic growth initiatives including:
a potentially transformative acquisition to secure long-term revenue growth;
investments in novel technologies that complement and future-proof its drug discovery platform;
expansion of its drug candidate discovery and early development into new target classes; and
in-licensing late-stage clinical assets to develop for the Japanese market
The balance of funds will support organic growth initiatives, and corporate purposes.

Second novel drug candidate resulting from multi-target drug discovery collaboration with Pfizer entered clinical trials – dosing of first subject by Pfizer triggered US$5 million payment to Sosei Heptares. PF-07054894, a CCR6 antagonist targeting Inflammatory Bowel Disease, originating from the Pfizer/Sosei Heptares collaboration, was nominated for clinical development by Pfizer in June 2019.
Enerzair Breezhaler approved in Europe for asthma – the approval, which closely follows approval in Japan, also includes an optional digital companion with sensor and app designed to improve compliance and to better support therapeutic decisions. Sosei Heptares received a US$5 million milestone payment from Novartis on this milestone being reached.
Positive clinical trial results published by Novartis show benefit of Enerzair Breezhaler (QVM149) in uncontrolled asthma – results from Phase 3 IRIDIUM trial published in The Lancet Respiratory Medicine, and post hoc analysis showing high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose published at the European Respiratory Society (ERS) Virtual International Congress 2020.
Japan investor relations team expanded – top-ranked investment analyst Hironoshin Nomura joins as Senior Vice President, Investor Relations and Corporate Strategy
Post-period Highlights

Creation of new company – Tempero Bio – with specialist venture capital firm Aditum Bio (founded by ex-Novartis executives Joe Jimenez and Mark Fishman) – Tempero in-licensed Sosei Heptares’ Phase 1 mGlu5 negative allosteric modulator program to develop novel therapeutics targeting addiction and anxiety. Sosei Heptares received an upfront payment and strategic equity stake in Tempero Bio and is eligible to receive future success-based development and commercial milestone payments plus tiered royalties from any future product sales.
Financial Highlights for the Nine-month Period ended 30 September 2020

Revenue totalled JPY 4,443 million (US$41 million*), a decrease of JPY 3,327 million (US$30 million) vs. the prior corresponding period. This was primarily due to there being two US$5m milestone receipts from existing collaborations, whereas the prior corresponding period included a one-off US$15 million major milestone payment from AstraZeneca, plus substantial upfront fees from partnering activities. Timing of new business development deals and progress related to existing programs can vary considerably from quarter to quarter. The Company expects to achieve new upfront and milestone payments later in the fiscal year.
Cash R&D expenses were carefully managed and totalled JPY 2,411 million (US$22 million), a decrease of JPY 476 million (US$4 million) vs. the prior corresponding period. This was primarily related to a reduction in project activity caused by the operational impact of the COVID-19 pandemic, as well as the successful recovery of excess costs incorrectly charged by one supplier. In the period under review, 96% of R&D spend related to UK operations.
Cash G&A expenses totalled JPY 1,339 million (US$12 million), a decrease of JPY 293 million (US$2 million) vs. the prior corresponding period, and was primarily related to a reduction in UK National Insurance liability linked to share-based payments as a result of the decline in the Company’s share price over the period.
Cash earnings** totalled JPY 314 million (US$3 million) vs. a cash earnings of JPY 2,705 million (US$25 million) in the prior corresponding period. The main reason for the decrease was due to the decrease in revenue as stated above.
Net loss totalled JPY 1,642 million (US$15 million) vs. a net profit of JPY 1,461 million (US$13 million) in the prior corresponding period. The main reason for the net loss was due to the decrease in revenue as stated above.
Cash and cash equivalents increased by JPY 22,425 million from the beginning of the year and amounted to JPY 37,800 million as at September 30, 2020.
Net cash provided by financing activities for the period under review totalled JPY 20,678 million. This was primarily due to net cash inflows from the issuance of new shares raising JPY 5,134 million (including shares issued through an international offering) and the issuance of convertible bonds raising JPY 15,902 million.
*Convenience conversion to US$ at the following rates: 2020: 1US$ =107.566 JPY; 2019: 1US$ =109.130 JPY

Sutro Biopharma to Participate in Four Upcoming Investor Conferences

On November 11, 2020 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, reported that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences in November and December of 2020 (Press release, Sutro Biopharma, NOV 11, 2020, View Source [SID1234570625]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentations Details:

2020 Stifel Virtual Healthcare Conference
Format: Corporate Presentation
Date: Monday, Nov. 16, 2020
Time: 3:20pm ET / 12:20pm PT

Jefferies Virtual London Healthcare Conference
Format: Virtual Fireside Chat
Date: Thursday, Nov. 19, 2020
Time: 12:35pm ET / 9:35am PT / 5:35pm GMT

Piper Sandler 32nd Annual Healthcare Conference
Format: Virtual Fireside Chat
Date: Tuesday, Dec. 1-3, 2020
Note: Fireside Discussion Available Nov. 23 through Dec. 3

3rd Annual Evercore ISI HealthCONx Conference
Format: Virtual Fireside Chat
Date: Thursday, Dec. 3, 2020
Time: 10:30am ET / 7:30am PT

Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company’s website at www.sutrobio.com. Archived replays of the webcasts will be available on the company’s website for approximately 30 days following each live presentation.

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

On November 11, 2020 I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported new preclinical data from in vivo and in vitro studies of its C5aR antibody project, TJ210/MOR210, at the 2020 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (Press release, I-Mab Biopharma, NOV 11, 2020, View Source [SID1234570624]). The data will be shared in an oral presentation entitled "TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy", on November 12, 2020 at 11:30 am EST (Abstract #607).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Complement component fragment 5a receptor (C5aR1, CD88) is a G-protein coupled receptor (GPCR) that is being investigated as a potential new drug target in the field of immuno-oncology. Produced in the tumoral microenvironment, C5a acts as a chemoattractant to recruit, through its C5aR1 receptor, tumor-promoting cells such as myeloid derived suppressive cells (MDSCs), neutrophils and M2 macrophages to the tumor site, resulting in the inhibition of tumor-attacking immune cells and promotion of tumor progression.

TJ210/MOR210 is an anti-C5aR monoclonal antibody in-licensed from MorphoSys. It is designed to interact with the N-terminus of C5aR1 and induces anti-tumor properties by blocking the activation and migration of C5aR1-expressing myeloid cells. Key results from preclinical studies show that:

TJ210/MOR210 selectively binds to the N-terminus of C5aR1 with high affinity and is not cross-reactive to other related GPCRs.
Blockade of C5a/C5aR pathway inhibits the recruitment of tumor promoting cells, leading to the significant inhibition of tumor growth when combining with another immuno-oncology therapy, e.g. anti-PD-1 antibody.
TJ210/MOR210 demonstrated a good safety profile of a 4-week repeat dose GLP toxicity study in cynomolgus monkeys, with no observed adverse effects up to the highest dose tested at 200 mg/kg and no impact on neutrophils.
"TJ210/MOR210 is one of the innovative monoclonal antibodies in our differentiated pipeline that brings together the best of science in immuno-oncology," said Dr. Joan Shen, CEO of I-Mab. "We are eager to advance this innovative program in clinical development, which has the potential to address the unmet need in cancer for patients around the world."

The preclinical data provide new understanding of the underlying mechanism of TJ210/MOR210 and a strong scientific rationale for TJ210/MOR210 to be further evaluated as a potential treatment for cancers. I-Mab and MorphoSys recently announced that the U.S. Food & Drug Administration approved the Investigational New Drug (IND) application to initiate a phase 1 trial of TJ210/MOR210 for the treatment of relapsed or refractory advanced solid tumors.

About TJ210/MOR210

TJ210/MOR210 is a novel human antibody directed against C5aR derived from MorphoSys’s HuCAL Platinum technology. C5aR, the receptor of the complement factor C5a, is investigated as a potential new drug target in the field of immuno-oncology and autoimmune diseases. Tumors have been shown to produce high amounts of C5a, which, by recruiting and activating myeloid-derived suppressor cells (MDSCs), M2 macrophages and neutrophils, is assumed to contribute to an immune-suppressive pro-tumorigenic microenvironment. TJ210/MOR210 is intended to block the interaction between C5a and its receptor, thereby potentially neutralizing the immune suppressive function of C5a and enabling immune cells to attack the tumor.

HuCAL Platinum is a registered trademark of MorphoSys AG.

Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials

On November 11, 2020 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") reported that it will host a CD33 program update featuring two key opinion leaders (KOLs) today, November 11th at 4:15 PM ET (Press release, Actinium Pharmaceuticals, NOV 11, 2020, View Source [SID1234570622]). The event will feature KOLs Dr. Ehab Atallah from the Medical College of Wisconsin, the senior investigator of the Actimab-A CLAG-M combination trial and Dr. Gary Schiller from the University of California Los Angeles Health, the principal investigator for the Actimab-A venetoclax combination trial as well as members of Actinium’s management team. Both KOL’s will review data that was included in abstracts accepted for presentation at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. They will also provide their perspectives on the treatment landscape and medical need each trial potentially addresses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Actimab-A AML Combinations Update Call Details
Webcast link: View Source
Date: November 11, 2020
Time: 4:15 PM ET

Dr. Ehab Atallah, MD, is a Professor of Medicine and Section Head of Hematological Malignancies at the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital. Dr Atallah, as senior investigator, will review the Phase 1 data from the Actimab-A CLAG-M combination trial in relapsed or refractory acute myeloid leukemia (R/R AML) that demonstrated 100% remission in the third and planned final dose cohort. Further, 83% of patients (10/12) who received 3 or fewer prior lines of treatment achieved CR or CRi. Notably, 70% of CR/CRi patients (7/10) were MRD negative indicating a deep remission with no detectable disease. Dr. Atallah will also discuss the trial data in the context of data available for other treatment options, including recently approved and novel agents in development, in the fit R/R AML population.

Dr. Gary Schiller, MD, is the Director of Bone Marrow/Stem Cell Transplantation and Professor of Hematology-Oncology at UCLA. Dr. Schiller, a well-published clinical investigator in acute and chronic leukemias and other hematologic malignancies, is the principal investigator on the Phase 1/2 clinical trial of Actimab-A and venetoclax. Dr. Schiller will discuss the lack of viable treatment options for R/R AML and the available opportunity for combination regimens such as Actimab-A plus venetoclax. Last week, the company announced that first-in-human data in this combination trial had been accepted for poster presentation at ASH (Free ASH Whitepaper) in December. The trial is in the dose escalation phase with proof of concept data expected in 2021.

CD33 Program ASH (Free ASH Whitepaper) Abstract Links

Oral Presentation Title: A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML
Publication Number: 165
Link: View Source

Poster Title: Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study
Publication Number: 2875
Link: View Source

About Actinium’s CD33 Program

Actinium’s CD33 program is evaluating the clinical utility of Actimab-A, an ARC comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 or Ac-225. CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome, or MDS, as well as patients with multiple myeloma. The CD33 development program is driven by data from over one hundred and twenty-five treated patients, including a Phase 1/2 trial where Actimab-A produced a remission rate as high as 69% as a single agent. This clinical data is shaping a two-pronged approach for the CD33 program, where at low doses the Company is exploring its use for therapeutic purposes in combination with other modalities and at high doses for use for targeted conditioning prior to bone marrow transplant. Actinium currently has multiple clinical trials ongoing including the Phase 1 Actimab-A CLAG-M and Phase 1/2 Actimab-A venetoclax combination trials and is exploring additional CD33 ARC combinations with other therapeutic modalities such as chemotherapy, targeted agents or immunotherapy.